Vol 2, No 2 (2011)
Case report
Published online: 2011-07-15
Effectiveness of minimal dose of lenalidomide in the treatment of relapsed plasma cell myeloma
Hematologia 2011;2(2):204-208.
Abstract
We present a case of 63 year-old lady in the second relapse of plasma cell myeloma, initially
treated with cyclophosphamide, thalidomide, dexamethasone chemotherapy combined with high
dose chemotherapy and autologous hematopoietic stem cell transplantation and bortezomib
and dexamethasone in the first relapse afterwards, who developed a severe pancytopenia being
on standard dose of lenalidomide, that was started in the second relapse. We were forced to
minimalize the dose of lenalidomide to 5 mg every other day, administered with a standard
dexamethasone dose, and supported with growth factors. Such a treatment was reasonably safe
and produced complete response. The patient remains in complete remission on maintenance
therapy with lenalidomide.
Hematologia 2011; 2, 2: 204–208
Hematologia 2011; 2, 2: 204–208
Keywords: plasma cell myelomarelapselenalidomidemaintenance therapy
